TCDA   $0.084  -16.83% Market Closed

Tricida Inc
Last Events:

2023-03-29 Trend pattern changed from Not found to расходящийся клин с наклоном вниз.

2023-03-29 Signal in Stochastic changed from bullish to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-03-29 Trend pattern changed from расходящийся клин с наклоном вниз to Not found.

2023-03-29 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-03-28 Trend pattern changed from Not found to расходящийся клин с наклоном вниз.

2023-03-28 Signal in Stochastic changed from bullish to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-03-28 Trend pattern changed from расходящийся клин с наклоном вниз to Not found.

2023-03-28 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.


Current temperature: 1.88
ST: 0, Cor:

Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell ActivelyBuy Sell
macd Sell Sell -
stoch Sell Sell -
ma20 Sell - -
ma50 Sell - -
ma100 Sell - -
Candlestick PatternJan. 20, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US89610F1012
ceo Dr. Gerrit Klaerner Ph.D.
Website https://www.tricida.com
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.